In this study, we will assess the reproducibility of the observed dose-dependent inhibiting effect of CK on platelet aggregation.
ID
Source
Brief title
Condition
- Coronary artery disorders
- Embolism and thrombosis
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
ADP induced platelet aggregation (area under curve and final aggregation) with
different concentrations of creatine kinase added in vitro.
Secondary outcome
Endogenous plasma CK activity levels.
Background summary
People of African descent are reported to have attenuated platelet aggregation
and high creatine kinase (CK) activity. Creatine kinase affects the ADP/ATP
ratio through catalysis of the reaction: ADP + creatine phosphate (CrP) รณ ATP +
creatine. A greater flux through the reaction may lead to lower ADP and affect
platelet aggregation. In a pilot study, we found that adding human CK to
platelet-rich plasma attenuated ADP induced platelet aggregation.
Study objective
In this study, we will assess the reproducibility of the observed
dose-dependent inhibiting effect of CK on platelet aggregation.
Study design
Observational study.
Study burden and risks
The participants will attend once. After a short questionnaire, 6 tubes of
blood will be drawn for the measurement of the endogenous plasma CK activity
level and the platelet aggregation tests. With a low burden to the participant,
the resulting data might help explain clinically relevant ethnic differences in
platelet aggregation.
Meibergdreef 5
Amsterdam 1105AZ
NL
Meibergdreef 5
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
Women between 18 and 50 years old, with no known disease or drug use.
Exclusion criteria
Current disease, personal and family history of bleeding or coagulation abnormalities, intensive exercise in the three days prior to participation, drug use, use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) in the two weeks prior to participation, usage of the supplement creatine (or a creatine analogue), current smoking.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL48880.018.14 |